United States:
FDA Announces Recommendations For Acceptable Amounts Of Residual Solvents In Pharmaceuticals
09 November 2015
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In the October 16, 2015, Federal Register, FDA
announced the availability of draft recommendations for a new
permitted daily exposure ("PDE") for the residual solvent
triethylamine and a revised PDE for the residual solvent
methylisobutylketone, according to the maintenance procedures for
the guidance for industry titled "Q3C Impurities: Residual Solvents."
The document is intended to recommend acceptable amounts for the
listed residual solvents in pharmaceuticals for the safety of the
patient. Comments due December 15, 2015.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...